Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis
Highlights
- • FP-ISR is associated with high rates of re-intervention and occlusion
- • Turbo-PowerTM + DCB is a safe and effective method to treat complex FP-ISR lesions
- • Turbo-PowerTM + DCB improved the 12-month TLR rates
- • Turbo-PowerTM + DCB showed a trend towards improving the re-occlusion rates
- • A comparison between Turbo-PowerTM laser + DCB vs other LA devices + DCB is needed
Abstract
Background
Femoropopliteal (FP) artery in-stent restenosis (ISR) is associated with high rates of re-intervention and occlusion. The combined use of laser atherectomy (LA) with balloon angioplasty (BA) is superior to conventional balloon angioplasty (BA). Drug-coated balloons (DCBs) when combined with LA have provided additional efficacy for the treatment of FP-ISR. The aim of this study was to investigate the combination of DCB + LA with the recently approved Turbo-Power™ (Spectranetics Inc., Colorado Springs, CO, USA) LA device.